Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M. Does age predict outcome in patients with inflammatory breast cancer?. Am Surg. 2014;80(8):E221-E224.
Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S. The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Breast. 2013;22(Suppl 1):S119.
Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease
. JACC Cardiovasc Imaging. 2013;6(8):877-885.
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy
. J Clin Oncol. 2010;28(1):166-172.
Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. J Clin Oncol. 2010;28(15 Suppl):e19524.
Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W. Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Circulation. 2010;122(21 Suppl):A12766.
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Circulation. 2009;120(18 Suppl):S299.
Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
. Cancer Chemother Pharmacol. 2008;61(3):453-458.
Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.
Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW. Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.
Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
. Br J Cancer. 2006;95(3):260-265.
Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006;37(1):7-14.
Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
I have recommended this provider and facility to many people. This has been a year to remember but this facility and staff have made it pleasant. I have felt so welcomed and cared for with sincere people. This has definitely made an impression on all of my family and their friends as well. Several people have come here this year as a result of our praising this facility and your staff. I feel like the physicians can be trusted and really listen to your concerns. One of my relatives had to switch to another facility because of the new health care rules with her insurance plan and she is not happy with that. She was use to your level of care and other facilities just do not measure up to your standards of professionalism.
Very pleased with both the PA and Dr. Melin. Both expressed concern and asked questions about overall health issues.
Dr. Melin is excellent in answering questions, spending time with me and knowing my health condition.
Dr Melin and her PAs are always very friendly, caring, and helpful.
dr susan melin is my favorite, my best physician, out of ten physicians/surgeons i see. i have rec'd her to multiple friends who have been diagnosed with CA or family with CA. i have been very lucky to have "found" dr. melin....would not trade her for any other oncologist!!
Have recommended Dr. Melin to several people.
Dr. Melin is the best!
*Dr. Melin has my utmost respect. She has been an amazing oncologist, giving me exceptional care and taking seriously all concerns I have raised.